Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.

Patricia M. Danzon, Jonathan Ketcham

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals--Germany, the Netherlands, and New Zealand--and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices, and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insurance coverage. Although a major purpose of RP is to stimulate competition, theory suggests that the achievement of this goal is unlikely, and this is confirmed by the empirical evidence. Other effects of RP differ across countries in predictable ways, reflecting each country's system design and other cost-control policies. New Zealand's RP system has reduced reimbursement and limited the availability of new drugs, particularly more expensive drugs. Compared to these three countries, if RP were applied in the United States, it would likely have a more negative effect on prices of onpatent products because of the more competitive U.S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales.

Original languageEnglish (US)
Pages (from-to)1-54
Number of pages54
JournalFrontiers in health policy research / National Bureau of Economic Research
Volume7
StatePublished - 2004
Externally publishedYes

Fingerprint

Medicare
New Zealand
Netherlands
Germany
Costs and Cost Analysis
Pharmaceutical Preparations
Insurance Coverage
Cost Control
Marketing
Research

Cite this

@article{933aefc5382b423b94437b302a16e9ff,
title = "Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.",
abstract = "This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals--Germany, the Netherlands, and New Zealand--and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices, and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insurance coverage. Although a major purpose of RP is to stimulate competition, theory suggests that the achievement of this goal is unlikely, and this is confirmed by the empirical evidence. Other effects of RP differ across countries in predictable ways, reflecting each country's system design and other cost-control policies. New Zealand's RP system has reduced reimbursement and limited the availability of new drugs, particularly more expensive drugs. Compared to these three countries, if RP were applied in the United States, it would likely have a more negative effect on prices of onpatent products because of the more competitive U.S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales.",
author = "Danzon, {Patricia M.} and Jonathan Ketcham",
year = "2004",
language = "English (US)",
volume = "7",
pages = "1--54",
journal = "Frontiers in health policy research / National Bureau of Economic Research",
issn = "1096-231X",

}

TY - JOUR

T1 - Reference pricing of pharmaceuticals for Medicare

T2 - evidence from Germany, The Netherlands, and New Zealand.

AU - Danzon, Patricia M.

AU - Ketcham, Jonathan

PY - 2004

Y1 - 2004

N2 - This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals--Germany, the Netherlands, and New Zealand--and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices, and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insurance coverage. Although a major purpose of RP is to stimulate competition, theory suggests that the achievement of this goal is unlikely, and this is confirmed by the empirical evidence. Other effects of RP differ across countries in predictable ways, reflecting each country's system design and other cost-control policies. New Zealand's RP system has reduced reimbursement and limited the availability of new drugs, particularly more expensive drugs. Compared to these three countries, if RP were applied in the United States, it would likely have a more negative effect on prices of onpatent products because of the more competitive U.S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales.

AB - This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals--Germany, the Netherlands, and New Zealand--and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices, and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insurance coverage. Although a major purpose of RP is to stimulate competition, theory suggests that the achievement of this goal is unlikely, and this is confirmed by the empirical evidence. Other effects of RP differ across countries in predictable ways, reflecting each country's system design and other cost-control policies. New Zealand's RP system has reduced reimbursement and limited the availability of new drugs, particularly more expensive drugs. Compared to these three countries, if RP were applied in the United States, it would likely have a more negative effect on prices of onpatent products because of the more competitive U.S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales.

UR - http://www.scopus.com/inward/record.url?scp=15244359182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15244359182&partnerID=8YFLogxK

M3 - Article

C2 - 15612334

AN - SCOPUS:15244359182

VL - 7

SP - 1

EP - 54

JO - Frontiers in health policy research / National Bureau of Economic Research

JF - Frontiers in health policy research / National Bureau of Economic Research

SN - 1096-231X

ER -